A Dark Vector Cognition product

Item 16. Form 10-K Summary.

4K characters. Original on sec.gov · Markdown

Item 16. Form 10-K Summary.

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MARSH & McLENNAN COMPANIES, INC.
Dated:February 9, 2026By/S/ JOHN Q. DOYLE
John Q. Doyle President and Chief Executive Officer

Each person whose signature appears below hereby constitutes and appoints Asha Amin and Connor Kuratek, and each of them singly, such person’s lawful attorneys-in-fact and agents, with full power to them and each of them to sign for such person, in the capacity indicated below, any and all amendments to this Annual Report on Form 10-K filed with the Securities and Exchange Commission.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated this 9th day of February, 2026.

NameTitleDate
/S/ JOHN Q. DOYLE John Q. DoyleDirector, President & Chief Executive OfficerFebruary 9, 2026
/S/ MARK C. MCGIVNEY Mark C. McGivneyChief Financial OfficerFebruary 9, 2026
/S/ STACY M. MILLS Stacy M. MillsVice President & Controller (Chief Accounting Officer)February 9, 2026
/S/ ANTHONY K. ANDERSON Anthony K. AndersonDirectorFebruary 9, 2026
/S/ BRUCE BROUSSARD Bruce BroussardDirectorFebruary 9, 2026
/S/ H. EDWARD HANWAY H. Edward HanwayDirectorFebruary 9, 2026
/S/ JUDITH HARTMANN Judith HartmannDirectorFebruary 9, 2026
/S/ DEBORAH C. HOPKINS Deborah C. HopkinsDirectorFebruary 9, 2026
/S/ TAMARA INGRAM Tamara IngramDirectorFebruary 9, 2026
/S/ JANE H. LUTE Jane H. LuteDirectorFebruary 9, 2026
/S/ STEVEN A. MILLS Steven A. MillsDirectorFebruary 9, 2026
/S/ MORTON O. SCHAPIRO Morton O. SchapiroDirectorFebruary 9, 2026
/S/ JAN SIEGMUND Jan SiegmundDirectorFebruary 9, 2026
/S/ LLOYD M. YATES Lloyd M. YatesDirectorFebruary 9, 2026

Previous: Item 15. Exhibits and Financial Statement Schedules. †